AstraZeneca chair Johansson to retire in 2023 after 11 years in role
Reuters
Published Feb 22, 2022 06:21AM ET
Updated Feb 22, 2022 08:16AM ET
By Pushkala Aripaka
(Reuters) -AstraZeneca non-executive Chairman Leif Johansson will retire next year after serving 11 years in the role, the Anglo-Swedish drugmaker said on Tuesday, as it moves onto the next stage of growth led by newer therapies, including for cancer.
The Swedish businessman, 70, became chairman in 2012, around the same time Frenchman Pascal Soriot took charge as chief executive. Soriot in an interview with the Financial Times https://on.ft.com/3zapoJp last May hinted that succession planning had begun for him and Johansson.
The London-listed drugmaker said on Tuesday that Johansson would step down following the annual general meeting in 2023 and the search for a chair successor was "proceeding well."
AstraZeneca (NASDAQ:AZN) last year asked Johansson to continue in his role to oversee its now-completed $39 billion acquisition of rare diseases drug maker Alexion (NASDAQ:ALXN), its biggest deal on record, while it also navigated developments around its COVID-19 shot.
He also served as chairman of telecommunications firm Ericsson (BS:ERICAs) from 2011 until 2018.
New governance codes introduced in 2019 to diversify talent said that a chair for a firm in Britain should not remain in the post beyond nine years, and companies must carefully consider any extension beyond that for a limited period.
AstraZeneca said on Tuesday it had once again asked Johansson, who reached nine years' tenure in 2021, to continue for another year until 2023 to facilitate the succession planning.
"The Board believes it would be in the best interests of shareholders for Mr Johansson to seek re-election at the AGM in April 2022 and continue to serve as Chair for one further year," it said in a statement.
Following confirmation of Johansson's retirement plans, Soriot's tenure could come back into investor focus as it leaves behind only him from the old guard at the top. Former finance chief Marc Dunoyer was moved to a new role to lead Alexion.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.